YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells
Version 2 2024-06-06, 01:30
Version 1 2015-03-19, 15:03
journal contribution
posted on 2015-01-01, 00:00 authored by S M Cheng, Y C Chang, C Y Liu, J Y Lee, H H Chan, C W Kuo, K Y Lin, S L Tsai, S H Chen, C F Li, E Leung, Jagat Kanwar, C C Huang, J Y Chang, C H CheungThe aim of this study was to determine the potency and molecular mechanism of action of YM155, a first-in-class survivin inhibitor that is currently under phase I/II clinical investigations, in various drug-resistant breast cancers including the oestrogen receptor positive (ER(+) ) tamoxifen-resistant breast cancer and the caspase-3-deficient breast cancer.
History
Journal
British journal of pharmacologyVolume
172Issue
1Pagination
214 - 234Publisher
WileyLocation
London, Eng.Publisher DOI
eISSN
1476-5381Language
engPublication classification
C Journal article; C1 Refereed article in a scholarly journalCopyright notice
2015, John Wiley & SonsUsage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC